Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
CD4+CD25+ regulatory T cells (T reg cells) play a key role in controlling autoimmunity and inflammation. Therefore, therapeutic agents that are capable of elevating numbers or increasing effector functions of this T cell subset are highly desirable. In a previous report we showed that a superagonistic monoclonal antibody specific for rat CD28 (JJ316) expands and activates T reg cells in vivo and upon short-term in vitro culture. Here we demonstrate that application of very low dosages of the CD28 superagonist into normal Lewis rats is sufficient to induce T reg cell expansion in vivo without the generalized lymphocytosis observed with high dosages of JJ316. Single i.v. administration of a low dose of the CD28 superagonist into Dark Agouti (DA) rats or Lewis rats that suffered from experimental autoimmune encephalomyelitis (EAE) proved to be highly and equally efficacious as high-dose treatment. Finally, we show that T reg cells that were isolated from CD28-treated animals displayed enhanced suppressive activity toward myelin basic protein–specific T cells in vitro, and, upon adoptive transfer, protected recipients from EAE. Our data indicate that this class of CD28-specific monoclonal antibodies targets CD4+CD25+ T reg cells and provides a novel means for the effective treatment of multiple sclerosis and other autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The antibody had specificity for the C’’D loop of the CD28 glycoprotein and had the unique capacity to activate T-cells solely through CD28 (signal 2) without the usual ligation of the T-cell receptor (signal 1) [27].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“leading, as of today, to 25 original publications describing efficacious therapy in a large number of rat and mouse disease models”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“similar reagents had shown efficacy in rodent models for treating autoimmune disease (2-4).”
From The calm after the cytokine storm: lessons from the TGN1412 trial (2008) · cites this paper as [2]
In the citing paper
“Titration of the CD28SA in vivo revealed that at high doses, both conventional T cells and Treg cells were activated, whereas at low doses, only Treg cells expanded measurably, providing a window for selective targeting of that subset [3].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · cited 1×
“” The cytokines IL-4 and IL-13 were responsible for this alternative activation of macrophages that led to the production of antiinflammatory cytokines by the macrophage (42).”
BackgroundPark, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 13×
“Experiments with human T reg cell clones further showed that expression of CTLA-4 positively correlated with their suppressive capacity (22, 23).”
BackgroundInfluentialRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Cited by
Items 101–200 of 206
Findlay, L., Sharp, G., Fox, B., Ball, C., Robinson, C. J., Bird, C., Stebbings, R., Eastwood, D., Wadhwa, M., Poole, S., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.03.019 · Cited by 29
Beyersdorf, N., Ding, X., Blank, G., Dennehy, K. M., Kerkau, T., & Hünig, T. (2008) · Blood · doi:10.1182/blood-2008-03-146662 · Cited by 32
Self-citationCai, Y., Xu, T., Lu, C., Ma, Y., Chang, D., Zhang, Y., Gu, X., & Ju, S. (2020) · Translational Stroke Research · doi:10.1007/s12975-020-00808-x · Cited by 28
Doerck, S., Göbel, K., Weise, G., Schneider‐Hohendorf, T., Reinhardt, M., Hauff, P., Schwab, N., Linker, R. A., Mäurer, M., Meuth, S. G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015478 · Cited by 28
“The rates of Treg within the spleen were comparable to the numbers known from the literature [28].”
Fritzsching, B., Korporal, M., Haas, J., Krammer, P. H., Suri‐Payer, E., & Wildemann, B. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.09.006 · Cited by 28
Animal extrapolation in preclinical studies: An analysis of the tragic case of TGN1412
Lemoine, M. (2016) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2016.12.004 · Cited by 28
The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy
Kim, H. J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0153 · Cited by 29
Superagonistic CD28 Antibody Induces Donor-Specific Tolerance in Rat Renal Allografts
Azuma, H., Isaka, Y., Li, X., Hünig, T., Sakamoto, T., Nohmi, H., Takabatake, Y., Mizui, M., Kitazawa, Y., Ichimaru, N., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02358.x · Cited by 28
“Although it remains unclear why application of superagonistic CD28 antibody led to a difference in outcome between this Phase I trial (24) and the preclinical trials (6,7), it is suggested that our observations may not be directly applicable in a clinical setting.”
BackgroundMethodLarge‐scale expansion of rat CD4+ CD25+ Treg cells in the absence of T‐cell receptor stimulation
Beyersdorf, N., Balbach, K., Hünig, T., & Kerkau, T. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02455.x · Cited by 32
Self-citationThe Northwick Park tragedy ? protecting healthy volunteers in future first-in-man trials
Dowsing, T., & Kendall, M. J. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00808.x · Cited by 25
Bending, D., & Lab), M. O. (. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13194 · Cited by 27
“TGN1412 was developed as an immunosuppressive treatment after an anti-CD28 antibody was found to suppress autoimmune reactions in rodent models [8].”
BackgroundCD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation
Hünig, T., Lühder, F., Elflein, K., Gogishvili, T., Fröhlich, M., Guler, R., Cutler, A. J., & Brombacher, F. (2010) · Medical Microbiology and Immunology · doi:10.1007/s00430-010-0156-z · Cited by 30
Diversity of regulatory T cells to control arthritis.
van Roon, J. V., Bijlsma, J., & Lafeber, F. (2006) · Baillière's Best Practice & Research : Clinical Rheumatology · doi:10.1016/j.berh.2006.06.006 · Cited by 29
Midkine and multiple sclerosis
Takeuchi, H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12499 · Cited by 24
CD8+ T cell help is required for efficient induction of EAE in Lewis rats
Camara, M., Beyersdorf, N., Fischer, H. J., Herold, M. J., Ip, C. W., van den Brandt, J., Toyka, K. V., Taurog, J. D., Hünig, T., Herrmann, T., et al. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.04.014 · Cited by 27
Self-citationMontag, T., Spreitzer, I., Löschner, B., Unkelbach, U., Flory, E., Sanzenbacher, R., Schwanig, M., & Schneider, C. K. (2007) · ALTEX · doi:10.14573/altex.2007.2.81 · Cited by 28
Mehrishi, J. N., Szabó, M., & Bakács, T. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.078 · Cited by 26
T cell immunomodulation—the Holy Grail of therapeutic tolerance
Isaacs, J. D. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.05.001 · Cited by 22
Farzaneh, L., Kasahara, N., & Farzaneh, F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0189-8 · Cited by 23
“However, this preferential expansion of T regs was no longer detectable at the higher dose of 5 mg/kg [ 27 ].”
BackgroundResultInfluentialPaterka, M., Voß, J. O., Werr, J., Reuter, E., Heinrich, S., Leuenberger, T., Herz, J., Radbruch, H., Bopp, T., Siffrin, V., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.09.008 · Cited by 25
Regulatory T cells in ischemic cardiovascular injury and repair
Zhuang, R., & Feinberg, M. W. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.08.004 · Cited by 21
Modification of accessory molecule signaling
Crow, M. K. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0018-3 · Cited by 20
“Provocative data suggest that the ligation of CD28 on Tregs, even in the absence of TCR ligation, can drive the proliferation and increased survival of those cells [18, 19].”
BackgroundInfluentialAbdoli, R., & Najafian, N. (2014) · International Journal of Organ Transplantation Medicine · Cited by 26
Inflammatory and Autoimmune Reactions in Atherosclerosis and Vaccine Design Informatics
Jan, M., Meng, S., Chen, N. C., Mai, J., Wang, H., & Yang, X. (2010) · BioMed Research International · doi:10.1155/2010/459798 · Cited by 21
“[84] N.”
Langenhorst, D., Gogishvili, T., Ribechini, E., Kneitz, S., McPherson, K., Lutz, M. B., & Hünig, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050080 · Cited by 19
“We and others have previously shown that such mAb are effective expanders and activators of Tregs in rats [17,18] and mice [19,20,21], allowing interference with multiple model diseases of autoimmunity, graft rejection and inflammation [22].”
BackgroundYang, T., Liu, P.-J., Sun, Q.-Y., Wang, Z., Yuan, G.-B., Fan, Z.-X., Ma, L., Lu, J.-F., Yuan, B.-Y., Zou, W.-L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-56739-2 · Cited by 20
“However, these expanded CD4 + CD25 + Tregs are polyclonal when stimulated with a CD28 superagonist in vivo or concurrently with a CD3/CD28 monoclonal antibody (MoAb) plus high-dose interleukin (IL)-2 in vitro 14,15 .”
BackgroundSun, Y., Zhou, L., Gu, X., Zhao, J., Bi, J., & Pan, L. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010140 · Cited by 19
Copsel, S. N., Wolf, D., Komanduri, K. V., & Levy, R. B. (2019) · Haematologica · doi:10.3324/haematol.2018.198838 · Cited by 19
Gonsette, R. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1103 · Cited by 18
“In the acute and chronic models of experimental allergic encephalomyelitis (EAE) in mice [55] and rats [56], PIX was found to be as effective and definitely less toxic than MX. Interestingly, the in vitro and in vivo immunosuppressive effects of PIX on the cellular and humoral components of the immune system are the s…”
BackgroundInfluentialMedina, M. Á., Couturier, J. P., Feske, M. L., Mahne, A. E., Turner, M. A., Yu, X., Kozinetz, C. A., Orozco, A. F., Hutchison, A. T., Savidge, T., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0511264 · Cited by 20
Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice
Lee, W. W. L., Teo, T., Lum, F., Andiappan, A. K., Amrun, S. N., Rénia, L., Rötzschke, O., & Ng, L. F. P. (2016) · Scientific Reports · doi:10.1038/srep37603 · Cited by 18
Novel therapies for rheumatoid arthritis
Tremoulet, A. H., & Albani, S. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.11.1427 · Cited by 19
“In the rat experimental autoimmune encephalomyelitis model, low doses of TGN1412 stimulated T-regulatory cell expansion [98].”
BackgroundPanoskaltsis, N., McCarthy, N. E., Stagg, A. J., Mummery, C. J., Husni, M., Arebi, N., Greenstein, D., Price, C. L., Al-Hassi, H. O., Koutinas, M., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02725-2 · Cited by 16
Singh, M., Basu, S., Camell, C. D., Couturier, J. P., Nudelman, R. J., Medina, M. Á., Rodgers, J. R., & Lewis, D. E. (2008) · European Journal of Immunology · doi:10.1002/eji.200737929 · Cited by 17
Manipulation of Regulatory T-Cell Function by Immunomodulators: A Boon or a Curse?
Fort, M. M., & Narayanan, P. K. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq136 · Cited by 15
“(2005) demonstrated that a rat CD28SA was highly effective in vivo in expanding the size and enhancing the activity of the Treg compartment, leading to substantial therapeutic success in rat models of autoimmunity and inflammation (Beyersdorf et al., 2005).”
BackgroundWei, P., Kou, W., Fu, J. L., Chen, Z., & Pan, F. (2023) · Communications Biology · doi:10.1038/s42003-023-05104-6 · Cited by 14
“It has been elucidated that the adoptive transfer of Tregs somehow prevents or decrease the severity of experimental autoimmune encephalomyelitis (EAE) and neurological symptoms 69 .”
Gosemann, J., Kuebler, J. F., Pozzobon, M., Neunaber, C., Hensel, J. H. K., Ghionzoli, M., Coppi, P. D., Ure, B. M., & Holze, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035512 · Cited by 14
“Intracellular staining of forkhead box protein 3 (Foxp3), a well-established Treg marker, was performed as described elsewhere [22].”
Regulatory T-cell subsets and their roles in transplantation tolerance
Chen, W., & Zhang, L. (2006) · Current Opinion in Organ Transplantation · doi:10.1097/01.mot.0000236699.52834.6f · Cited by 14
Zhong, S., Xiang, Y., Liu, P.-J., He, Y., Yang, T., Wang, Y., Ai, R., Zhang, J., & Liu, G.-Z. (2017) · PubMed Central · doi:10.4103/0366-6999.215335 · Cited by 13
“[13,14] Animal studies have shown that the symptoms of EAE, an animal model of MS, were remarkably alleviated after the adoptive transfer of CD4+ CD25+ Treg in mice.[15] However, marked disease deterioration was observed in EAE mice if CD4+ CD25+ Tregs were removed,[16] especially in the mouse model of EAE induced by…”
BackgroundMichaelis, K., Wallbrecht, K., Kerstan, A., Beyersdorf, N., Williams, C. A., Kerkau, T., Wang, X., Hünig, T., & Schön, M. P. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.01031.x · Cited by 14
Self-citationBakács, T., Mehrishi, J. N., Szabados, T., Varga, L., Szabó, M., & Tusnády, G. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000103282 · Cited by 13
“the first ever administration of a single dose of a novel ‘superagonist’ anti-CD28 monoclonal antibody TGN1412 [”
BackgroundIntervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease
Kwon, B. (2010) · Experimental & Molecular Medicine · doi:10.3858/emm.2010.42.10.071 · Cited by 12
“CD28 superagonist mAbs have been shown to selectively expand Treg cells and be effective in treating experimental autoimmune encephalomyelitis in rats (Beyersdorf et al., 2005).”
BackgroundThe T cell-selective IL-2 mutant AIC284 mediates protection in a rat model of Multiple Sclerosis
Weishaupt, A., Paulsen, D., Werner, S., Wolf, N., Köllner, G., Rübsamen‐Schaeff, H., Hünig, T., Kerkau, T., & Beyersdorf, N. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.03.020 · Cited by 12
“However, the unaltered basic suppressive activity of Treg cells after AIC284 treatment in vivo precluded transfer of protection from AIC284-treated animals to therapy-naïve EAE rats as we had seen with Treg cells from rats treated with a superagonistic anti-CD28 mAb (Beyersdorf et al., 2005).”
BackgroundMethodSelf-citationMiyasato, K., Takabatake, Y., Kaimori, J., Kimura, T., Kitamura, H., Kawachi, H., Li, X., Hünig, T., Takahara, S., Rakugi, H., et al. (2010) · Clinical and Experimental Nephrology · doi:10.1007/s10157-010-0370-4 · Cited by 14
“A similar phenomenon was observed in the experimental autoimmune encephalomyelitis (EAE) model of Lewis rats treated with CD28SA [ 8 ].”
BackgroundResultGladow, N., Hollmann, C., Ramos, G. C., Frantz, S., Kerkau, T., Beyersdorf, N., & Hofmann, U. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227734 · Cited by 12
Self-citationHuman-like Response of Pig T Cells to Superagonistic Anti-CD28 Monoclonal Antibodies
Uehlein, S., Ding, X., Flößer, J., Schmidt, S., Steitz, J., Bille, M., Schnitter, F., Baltes, S., Saalmüller, A., Gerner, W., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100174 · Cited by 15
Self-citationStabilizing Human Regulatory T Cells for Tolerance Inducing Immunotherapy
He, X., Koenen, H. J. P. M., Slaats, J., & Joosten, I. (2017) · Immunotherapy · doi:10.2217/imt-2017-0017 · Cited by 13
Hoen, E. N. M. N., Boot, E. P. J., Wagenaar-Hilbers, J. P. A., van Bilsen, J. H. M., Arkesteijn, G. J. A., Storm, G., Everse, L. A., van Eden, W., & Wauben, M. H. M. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0607436 · Cited by 12
“recently [19].”
Treatment and Prevention of Experimental Autoimmune Myocarditis with CD28 Superagonists
Wang, S., Liu, J., Wang, M., Zhang, J., & Wang, Z. (2009) · Cardiology · doi:10.1159/000256660 · Cited by 12
“which suggests that the proliferation of T regs induced by anti-CD28 mAbs is beneficial and tolerated. Some progress has therefore been achieved in the fundamental research on the application of anti-CD28 mAbs for the treatment of autoimmune diseases such as experimental autoimmune encephalomyelitis [”
BackgroundTargeting CD28 to prevent transplant rejection
Yeung, M. Y., Najafian, N., & Sayegh, M. H. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.863875 · Cited by 11
“Although CD28 costimulation results in activation of various T-cell subsets (including effector cells), when CD28 superagonists were administered in animal models, the predominate response was a massive expansion and functional activation of Tregs, with minimal expansion of conventional CD4 T cells [127-129].”
BackgroundTakabatake, Y., Li, X., Mizui, M., Miyasato, K., Matsui, I., Kawada, N., Imai, E., Hünig, T., Takahara, S., Wada, T., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00229 · Cited by 9
T cells stimulatedin vitrohave a suppressive function but do not contain only regulatory T cells
Valencic, E., Piscianz, E., Tommasini, A., & Granzotto, M. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03502.x · Cited by 9
Qeska, V., Barthel, Y., Iseringhausen, M., Tipold, A., Stein, V. M., Khan, M. A., Baumgärtner, W., & Beineke, A. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.10.006 · Cited by 8
Schneider, C. K., & Kalinke, U. (2007) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-007-0331-6 · Cited by 8
Kawaguchi, A. T., Kametani, Y., Kato, S., Furuya, H., Tamaoki, K., & Habu, S. (2009) · Artificial Organs · doi:10.1111/j.1525-1594.2008.00703.x · Cited by 8
Zinöcker, S., Dressel, R., Wang, X., Dickinson, A. M., & Rolstad, B. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00355 · Cited by 8
“Furthermore, we found that host-derived FoxP3-expressing CD4+ CD25+ T cells, comprising a regulatory T cell subtype (Beyersdorf et al., 2005), reconstituted relatively quickly and were present at normal levels in peripheral blood at 4 weeks post-transplant (Zinöcker et al., 2011a).”
BackgroundT-cell response dynamics in animal models of multiple sclerosis: implications for immunotherapies
Schreiner, B., Bailey, S. L., & Miller, S. D. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.1.57 · Cited by 7
Paletta, D., Fichtner, A. S., Hahn, A. M., Starick, L., Beyersdorf, N., Monzón‐Casanova, E., Mueller, T. D., & Herrmann, T. (2015) · European Journal of Immunology · doi:10.1002/eji.201545534 · Cited by 7
Self-citationLangenhorst, D., Tabares, P., Gulde, T., Becklund, B. R., Berr, S., Surh, C. D., Beyersdorf, N., & Hünig, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01985 · Cited by 9
“With regard to CD28SA-mediated polyclonal Treg activation, pronounced therapeutic effects have been observed not only in rodent models for major human autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, or type 1 diabetes (14, 30, 31) but also in graft versus host disease (32, 33), solid-organ transp…”
BackgroundSelf-citationTHE ROLE OF REGULATORY T CELLS IN THE DEVELOPMENT OF AUTOIMMUNE PROCESS IN MULTIPLE SCLEROSIS
Eliseeva, D. D., Завалишин, И. А., Karaulov, A. V., & Bykovskaya, S. N. (2012) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn.v67i3.188 · Cited by 9
Introduction of a Biologic Agent into the Clinic
Strand, V., & Smith, J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-9993-2.00033-3 · Cited by 6
Embracing the heterogeneity of natural viruses in mouse studies
Fiege, J. K., & Langlois, R. A. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001758 · Cited by 7
“CD28SA treatment in SPF rats resulted in expanded antiinflammatory T regulatory cells (Tregs), but in humans led to activation of inflammatory T cells and cytokine storm [3, 57, 58].”
BackgroundT Cell Activation and Function: Role of Signal Strength
Ahmed, A., & Nandi, D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7725-0_4 · Cited by 6
Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Dunne, P. J., & Fletcher, J. M. (2010) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/187221310793564182 · Cited by 6
“TGN1412 selectively enhanced Treg cell numbers and function in vivo (93).”
BackgroundFirst-in-human trials with therapeutic proteins: regulatory rethink?
Schneider, C. K. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.3.327 · Cited by 6
McCarthy, N. E., Stagg, A. J., Price, C. L., Mann, E. R., Gellatly, N. L., Al-Hassi, H. O., Knight, S. C., & Panoskaltsis, N. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02723-4 · Cited by 5
Haack, S., Baiker, S., Schlegel, J. A., Sauer, M., Sparwasser, T. D., Langenhorst, D., & Beyersdorf, N. (2020) · European Journal of Immunology · doi:10.1002/eji.202048803 · Cited by 5
Self-citationSeki, H. (2017) · Hypertension Research in Pregnancy · doi:10.14390/jsshp.hrp2017-015 · Cited by 6
Shi, Q., Niu, Y., Cao, H., Zhou, X., Jiang, S., Liu, Z., & Fan, H. (2012) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.02.009 · Cited by 5
“Our observation suggests that the application of very low dosages of SupCD28 MAb to a rat OTT model is sufficient to induce Treg cell expansion in vivo without the generalized lymphocytosis observed with high doses of SupCD28 MAb.(18) SupCD28 MAb at 0.”
BackgroundResultInfluentialThe Immune Synapse as a Novel Target for Therapy
Graca, L. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8296-4 · Cited by 5
Liang, Y., Xue, N., Wang, X., Ding, X., & Fang, Y. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1581-x · Cited by 4
“CD28sa amplifies T cell receptor (TCR) signals and is observed to have pronounced therapeutic effects in rodent models for infection-associated inflammation [22], solid-organ transplantation [23–25], rheumatoid arthritis [26] and ischemic organ injury [14, 19].”
BackgroundFrom mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic
Ng, W., & Isaacs, J. D. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8296-4_12 · Cited by 4
“For example, infections may play a key role in initiating autoimmune responses and transplant rejection [ 24 , 25].”
BackgroundRoelcke, V. (2022) · Science in Context · doi:10.1017/s0269889723000170 · Cited by 5
“Trials with animal models of rheumatoid arthritis and multiple sclerosis in mice and rats had confirmed this hypothesis: the rodents recovered from their conditions and did not show any side effects (Beyersdorf et al. 2005).”
BackgroundAzuma, H., Isaka, Y., Nomi, H., Inamoto, T., Li, X., Hőunig, T., Takabatake, Y., Ichimaru, N., Ibuki, N., Matsumoto, K., et al. (2010) · Transplantation · doi:10.1097/tp.0b013e3182007b59 · Cited by 3
“We then performed adoptive transfer experiments with nonspecific CD4 CD25 cells, which were purified by in vivo injection of CD28SA, to examine the following three subjects: (1) whether the induction of tolerance in this model was indeed mediated by CD28SA-expanded CD4 CD25 Tregs, (2) whether nonspecific CD4 CD25 Treg…”
BackgroundMethodInfluentialSelf-citationThe future of biological agents in the treatment of rheumatoid arthritis
Rawlings, C., & Choy, E. (2014) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.14.32 · Cited by 2
Hofstetter, H. H., Stüve, O., & Hartung, H.-P. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1417 · Cited by 2
Realizing the potential of agonistic antibody immunotherapy
Cragg, M. S., Yu, X., Paluch, C., & Davis, S. J. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01442-2 · Cited by 2
“Promising preclinical work had suggested that anti-CD28 superagonists would preferentially expand regulatory T cells in vivo 147 and prevent autoimmunity 148 , without being toxic.”
Large Animal Models of Transplantation
Anderson, D. J., Martin, B. M., Kirk, A. D., & Sachs, D. H. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch15 · Cited by 1
IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Brennan, F. R. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch36 · Cited by 1
Toda, T., & Nakamura, K. (2014) · Wiley eBooks · doi:10.1002/9783527676965.ch7 · Cited by 1
Multiple Sklerose und andere autoimmune ZNS-Erkrankungen
Kroner, A., Kleinschnitz, C., Stadelmann, C., Raab, P., Stangel, M., Trebst, C., Voß, E. V., & Cordes, A.-L. (2011) · Springer eBooks · doi:10.1007/978-3-642-20477-7_1 · Cited by 4
T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Brennan, F. R. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch32 · Cited by 1
Tolérance immunitaire vis-à-vis d’auto-antigènes du système nerveux : implications thérapeutiques
Liblau, R., & Cassan, C. (2007) · Revue Neurologique · doi:10.1016/s0035-3787(07)92155-4 · Cited by 1
Co‐Administration of Co‐Stimulatory Moieties
Arancibia-Cárcamo, C. V., & Latchman, Y. E. (2012) · Wiley eBooks · doi:10.1002/9781118345313.ch25
Castaneda, C., & LaPointe, M. S. (2011) · Wiley eBooks · doi:10.1002/9780470571224.pse437
Untired Regulatory T Cells: Untying Fatigue from T Cell Regulation in Multiple Sclerosis
Hofstetter, H. H., Smolianov, V., & Hartung, H. (2009) · European Neurology · doi:10.1159/000236376
T-cell costimulation blockade in immunologic diseases: role of CD28 family members
Clay, B. S., & Sperling, A. I. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.3.383
Signals Controlling Regulatory T Cell Differentiation and Homeostasis
Zou, T. (2012) · ScholarlyCommons (University of Pennsylvania)
Redirected T cell activity by high affinity TCR-ANTI-CD3 bispecific candidate therapeutics
Adams, K. J. (2013) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 1
TGN1412: Superagonist Dr. Jekyll and
Criado, G. (2006)
A Unique Gene Expression Profile to Identify Operationally Tolerant Liver Transplant Recipients
Rojas-Luengas, V. (2016) · TSpace (University of Toronto)
Biomimetic Delivery of Regulatory T Cell Inducing Factors to Suppress Cutaneous Inflammation
Balmert, S. C. (2018) · D-Scholarship@Pitt (University of Pittsburgh)
Die Rolle des ko-stimulatorischen Moleküls CD28 in verschiedenen Phasen der EAE
Hufschmidt, J. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6671
Choy, E. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00057-9
Midkine and Multiple Sclerosis
Takeuchi, H. (2012) · Springer eBooks · doi:10.1007/978-94-007-4234-5_12
Pathophysiology and Imaging Diagnosis of Demyelinating Disorders
Bernitsas, E. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-944-9 · Cited by 1
Gladow, N., Hollmann, C., Ramos, G. C., Frantz, S., Kerkau, T., Beyersdorf, N., & Hofmann, U. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235947
Self-citationThe Development, Indications, and the Safety of Monoclonal Antibodies
Güney, H. Z. (2023) · Lokman Hekim Health Sciences · doi:10.14744/lhhs.2023.12008
Humanizing a CD28 signaling domain affects CD8 activation, exhaustion and stem-like precursorsPreprint
Brady, A. E., Revu, S. K., Wu, D., Fisk, H., Kone, K., Lydecker, A., Purser, E. J., Smith, N. L., Hilt, Z. T., Woodyear, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.10.642460
“Pre-clinical mouse studies suggested CD28SA had potential to induce immunoregulation in settings of autoimmunity and allotransplantation by inducing significant expansion of Tregs ( 19, 20 ) ( 21 ).”
Metadata
- Authors
- Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R.
- Affiliations
- University of Würzburg (DE)
- Universitätsklinikum Würzburg (DE)
- 3TeGenero ImmunoTherapeutics AG, D-97076 Würzburg, Germany
- 1Institute for Virology and Immunobiology, University of Würzburg
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2005-08-01
- Volume
- 202
- Issue
- 3
- Pages
- 445-455
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2213080
- OpenAlex
- W2150928170
- Cited by
- 203
- References
- 48
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 2 · 2018: 7 · 2017: 7 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 9 · 2012: 19
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Funders
- Bundesministerium für Bildung und Forschung
- Bayerische Forschungsstiftung
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- regulatory T cells, experimental autoimmune encephalomyelitis, multiple sclerosis, adoptive T cell therapy, Treg cell expansion, immunosuppression, myelin basic protein, autoimmune disease therapy, Lewis rats, Dark Agouti rats
- MeSH terms
- Animals, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Dose-Response Relationship, Immunologic, Encephalomyelitis, Autoimmune, Experimental, Immunosuppression Therapy, Injections, Intravenous, Lymphocyte Activation, Multiple Sclerosis, Rats, Inbred Lew, Receptors, Interleukin-2, CD4-Positive T-Lymphocytes, CD28 Antigens, Cell Proliferation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.